Navigation ▼

Show simple item record

dc.contributor.advisor Bandelow, Borwin Prof. Dr.
dc.contributor.author Meiser, Miriam
dc.date.accessioned 2016-09-23T06:51:08Z
dc.date.available 2016-10-12T22:50:05Z
dc.date.issued 2016-09-23
dc.identifier.uri http://hdl.handle.net/11858/00-1735-0000-002B-7C0B-D
dc.language.iso deu de
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subject.ddc 610 de
dc.title Stellenwert des Opioidantagonisten Naltrexon bei stationär behandelten Borderline-Patienten de
dc.type doctoralThesis de
dc.title.translated Improvement of Borderline Personality Disorder with Naltrexone: Results of a retroperspective evaluation de
dc.contributor.referee Bandelow, Borwin Prof. Dr.
dc.date.examination 2016-10-05
dc.description.abstracteng Introduction: Although 85% of inpatients with Borderline Personality Disorder (BPD) receive psychotropic drug treatment, no drug is approved for this indication so far. A dysregulation of the endogenous opioid system (EOS) has been posed to underly the neurobiology of BPD. Accordingly, the opioid antagonist naltrexone might be helpful to treat symptoms of BPD. Two small studies showed limited differences of naltrexone vs. placebo on dissociation, which were not significant, perhaps due to the low power of the studies. Methods: A retrospective analysis of the charts of inpatients (n=161) with BPD was performed. Patients were classified as either treatment responders or non-responders. As all patients received multiple psychopharmacological treatments, stepwise logistic regression analysis was performed to detect, which drug contributed most to improvement of symptomatology. Results: None of the drugs applied contributed significantly to improvement, with the exception of naltrexone (odds ratio, p=2,9) Patients treated with naltrexone (n=55, 34,16%) recovered significantly more often and faster and, in particular, showed highly significant reduction of self-harm and suicidal thoughts. Higher doses of naltrexone treatment were more effective than low-dose treatment; however, the latter was still better than any other treatment. Conclusion: Large-scale double-blind studies are warranted to examine the efficacy of opioid antagonists (naltrexone, nalmefene) in BPD. de
dc.contributor.coReferee Friede, Tim Prof. Dr.
dc.contributor.thirdReferee Brockmöller, Jürgen Prof. Dr.
dc.subject.ger Borderline Persönlichkeitsstörung de
dc.subject.ger Naltrexon de
dc.subject.ger Opioidantagonist de
dc.subject.ger EOS de
dc.subject.ger Psychopharmakologie de
dc.subject.eng Borderline Personality Disorder de
dc.subject.eng Naltrexone de
dc.subject.eng endogenous opioid system de
dc.subject.eng inpatients de
dc.subject.eng Psychiatry de
dc.identifier.urn urn:nbn:de:gbv:7-11858/00-1735-0000-002B-7C0B-D-0
dc.affiliation.institute Medizinische Fakultät de
dc.subject.gokfull medizin de
dc.description.embargoed 2016-10-12
dc.identifier.ppn 869470183

Files in this item

This item appears in the following Collection(s)

Show simple item record